Postherpetic Neuralgia
Conditions
Brief summary
This is a study to evaluate the safety and efficacy of 4% and 8% w/w TV 45070 ointment compared with placebo ointment applied topically and twice daily to the area of PHN pain for 4 weeks in patients with PHN
Interventions
DRUGTV-45070
TV-45070 is an ointment applied topically twice daily to area of pain.
DRUGPlacebo
The matching placebo ointment contained only the excipients of the active treatment; also applied topically twice daily to area of pain.
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient has chronic Postherpetic Neuralgia (PHN), defined as pain present for more than 6 months and less than 10 years after onset of herpes zoster skin rash affecting a single dermatome. Patients with more than 1 involved dermatome may also be included, provided the affected dermatomes are contiguous. * Patient is ≥18 years of age, with a body mass index (BMI) between 18 and 34 kg/m2, inclusive, at the screening visit. * If the patient is a woman and is fertile, the patient is not pregnant and has negative pregnancy tests at both the screening and randomization visits, and agrees to use an acceptable method of contraception for the duration of the study, including follow-up. * If the patient is a man and is capable of producing offspring, the patient must agree to use an acceptable method of contraception, unless the partner cannot become pregnant for the duration of the study, including follow-up. * Patient must sign the written Informed Consent Form (ICF) for the study and be willing to comply with all study procedures and restrictions. * Patient must be judged by the investigator to be medically healthy (except for PHN) and able to participate in the study * Other criteria apply, please contact the investigator for more information
Exclusion criteria
* Patient has any other severe pain that might confound assessment or self-evaluation of pain due to PHN. * Patient has PHN affecting the face (trigeminal nerve distribution). * Patient has a history, in the judgment of the investigator, of inadequate response to more than 3 adequate courses of treatment with other medications used to treat neuropathic pain (eg, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, anticonvulsants, topical lidocaine, and/or topical capsaicin). * Patient is taking oral analgesics (either opioid or non-opioid) or is receiving topical therapy such as the 5% topical lidocaine patch for the treatment of pain and is unwilling or unable to complete a washout period during which the patient will discontinue analgesic therapy or topical pain therapy. * Patient has been treated with topical capsaicin at any time in the past 6 months for neuropathic pain. * Patient has a history of fibromyalgia. * Other criteria apply, please contact the investigator for more information
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline to Week 4 in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores Using a Mixed Model for Repeated Measures | Baseline (day -7 to day -1), Week 4 (day 22 to day 28) | The primary efficacy endpoint was the change from baseline to week 4 in the weekly average of the daily average NRS scores. The NRS is a widely-used, standard one-dimensional 11-point scale from 0=no pain to 10=worst pain imaginable as reported by patients. The daily average NRS scores is the average of the 2 NRS scores (recorded in the morning and evening) of average pain, defined as the patient-reported average pain intensity over the prior 12 hours. At least 1 of the 2 daily scores had to be recorded (non-missing) or the daily average was considered missing. Negative change from baseline values indicate a lessening of pain. The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the daily average NRS scores at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of the daily average NRS scores as covariate; and patient as a random effect. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline to Week 4 in the Weekly Average of the Average Numeric Rating Scale (NRS) Pain Scores Recorded in the Morning Using a Mixed Model for Repeated Measures | Baseline (day -7 to day -1), Week 4 (day 22 to day 28) | The NRS is a widely-used, standard one-dimensional 11-point scale from 0=no pain to 10=worst pain imaginable as reported by patients. The NRS pain scores recorded in the morning is defined as the patient-reported average pain intensity over the prior 12 hours. Negative change from baseline values indicate a lessening of pain. The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the evening NRS scores at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of morning NRS scores as covariate; and patient as a random effect. |
| Change From Baseline to Week 4 in the Weekly Average of the Worst Numeric Rating Scale (NRS) Pain Scores Recorded in the Evening Using a Mixed Model for Repeated Measures | Baseline (day -7 to day -1), Week 4 (day 22 to day 28) | The NRS is a widely-used, standard one-dimensional 11-point scale from 0=no pain to 10=worst pain imaginable as reported by patients. The worst pain is defined as the patient-reported worst pain intensity over the prior 24 hours. Negative change from baseline values indicate a lessening of pain. The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the worst pain NRS scores at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of the evening NRS scores as covariate; and patient as a random effect. |
| Percentage of Participants With >=30% and >=50% Improvement From Baseline in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores at Week 4 Using a Mixed Model for Repeated Measures | Baseline (day -7 to day -1), Week 4 (day 22 to day 28) | The NRS is a 11-point scale from 0=no pain to 10=worst pain imaginable as reported by patients. The daily average NRS scores is the average of the 2 NRS scores (recorded in the morning and evening) of average pain, defined as the patient-reported average pain intensity over the prior 12 hours. Percent improvement is calculated as 100 × (the weekly average of the daily average NRS pain score at week 4 - weekly average of the daily average NRS pain scores at baseline /weekly average of the daily average NRS pain scores at baseline. Patients missing a week 4 average are considered non-responders (\<50% improvement or \<30% improvement). The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the daily average NRS scores at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of the daily average NRS scores as covariate; and patient as a random effect. |
| Change From Baseline to Weeks 2 and 4 in the Neuropathic Pain Symptom Inventory (NPSI) Total Score Using a Mixed Model for Repeated Measures (MMRM) | Baseline (day 1 prior to dosing), Weeks 2 (day 15) and Week 4 (day 29) | NPSI is a patient-reported questionnaire to evaluate the severity of different symptoms of neuropathic pain. The questionnaire contains 10 descriptors representing 5 distinct dimensions of pain: burning pain, deep pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia, plus 2 temporal items. Descriptors are scored from 0 through 10, where higher scores represent worse pain. The total score is the sum of the scores of the 10 descriptors (Bouhassira et al 2004). The total score ranges from 0 (no pain) through 100 (worst pain imaginable). If the score for one question was missing the total score was computed as 10 times sum of scores of 9 descriptors divided by 9. If more than one question was missing then the total score was missing. Negative change from baseline scores indicated less pain. The MMRM used pooled study center, week, treatment, and treatment by week interaction as fixed factors and patient as a random factor. |
| Change From Baseline to Week 4 in the Neuropathic Pain Impact on Quality of Life (NePIQoL) Total Score | Baseline (day 1), Week 4 (day 29) | NePIQoL is a questionnaire that contains 41 items to evaluate quality of life in patients with neuropathic pain. Each question has responses ranging from strongly agree or always to strongly disagree or never. Questions are scored on a 5-point scale from 1 through 5, where higher scores represent greater pain-related interference in quality of life. Total range is 41 (great quality of life) to 205 (worst quality of life). Negative change from baseline scores indicated an improving quality of life. |
| Change From Baseline to Week 4 in the Weekly Average of the Average Numeric Rating Scale (NRS) Pain Scores Recorded in the Evening Using a Mixed Model for Repeated Measures | Baseline (day -7 to day -1), Week 4 (day 22 to day 28) | The NRS is a widely-used, standard one-dimensional 11-point scale from 0=no pain to 10=worst pain imaginable as reported by patients. The NRS pain scores recorded in the evening is defined as the patient-reported average pain intensity over the prior 12 hours. Negative change from baseline values indicate a lessening of pain. The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the evening NRS scores at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of the evening NRS scores as covariate; and patient as a random effect. |
| Change From Baseline to Weeks 2 and 4 in the Daily Sleep Interference Scale (DSIS) Using a Mixed Model for Repeated Measures | Baseline (day 1 prior to dosing), Weeks 2 (day 15) and Week 4 (day 29) | DSIS is an 11-point scale that asks the patient to select the number that best describes how much your pain has interfered with your sleep during the past 24 hours. Response options range from 0 (Did not interfere with sleep) to 10 (Completely interfered with sleep/unable to sleep due to pain). Negative change from baseline scores indicate improvement (lessening) of how much pain interfered with sleep. The MMRM used pooled study center, week, treatment, and treatment by week interaction as fixed factors and patient as a random factor. |
| Kaplan-Meier Estimates for First Time to Reach 30% or More Sustained Improvement in Weekly Average of the Daily Average NRS Pain Scores | Baseline (days -7 to -1), Week 1 (days 1-7), Week 2 (day 8-14), Week 3 (days 15-21), Week 4 (days 22-29) | Percent improvement is calculated as 100\*(the weekly average of the daily average NRS pain score - weekly average of the daily average NRS pain scores at baseline \[days -7 to -1\])/weekly average of the daily average NRS pain scores at baseline. Patients who do not reach \>= 30% improvement are censored at their last non-missing weekly average. Patients who reach \>= 30% improvement, but the improvement is not sustained through the end of the treatment period are censored at their last non-missing weekly average. For patients who reach \>= 30% improvement that is sustained through the end through the end of the of the treatment, the time \>= 30% improvement is first reached is used. |
| Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Brush-Evoked Allodynia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Baseline (day 1 prior to dosing), Weeks 2 (day 15) and Week 4 (day 29) | Allodynia refers to central pain sensitization (increased response of neurons) following normally non-painful, often repetitive, stimulation. In this case, pain evoked by innocuous brush is measured on an 11-point NRS where 0=no pain and 11=worst pain imaginable as reported by patients Negative change from baseline scores indicate improvement (lessening) of pain. |
| Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Punctate-Evoked Hyperalgesia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Baseline (day 1 prior to dosing), Weeks 2 (day 15) and Week 4 (day 29) | Hyperalgesia refers to increased pain from a stimulus that normally provokes pain. In this case, pain is evoked by punctate skin stimulation using a Medipin® and is measured on an 11-point NRS where 0=no pain and 11=worst pain imaginable as reported by patients. Negative change from baseline scores indicate improvement (lessening) of pain. The MMRM used pooled study center, week, treatment, and treatment by week interaction as fixed factors and patient as a random factor. The unstructured covariance matrix for repeated observations within patients was used. |
| Participants With Treatment-Emergent Adverse Events | day 1 up to day 57 | An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. |
| Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Weeks 2 (day 15) and Week 4 (day 29) | PGIC is a standardized self-report tool that measures the change in a patient's overall status rating since the start of treatment on 7-point scale (Hurst and Bolton 2004). The 7-point scale is defined as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. The MMRM used pooled study center, week, treatment, and treatment by week interaction as fixed factors and patient as a random factor. |
Countries
United States
Participant flow
Recruitment details
658 patients with chronic postherpetic neuralgia (PHN) were screened; reasons for not enrolling included: inclusion criteria not met (144), exclusion criteria met (171), consent withdrawn (28), lost to follow-up (6), adverse event (1), other (8).
Pre-assignment details
300 participants were randomly assigned in a 1:1:1 ratio to 1 of 3 treatment groups.
Participants by arm
| Arm | Count |
|---|---|
| TV-45070 4% TV-45070 ointment in a 4% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28. | 100 |
| TV-45070 8% TV-45070 ointment in a 8% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28. | 100 |
| Placebo Placebo ointment applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28. | 100 |
| Total | 300 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 3 | 3 | 2 |
| Overall Study | Lost to Follow-up | 0 | 0 | 1 |
| Overall Study | Other | 2 | 0 | 0 |
| Overall Study | Protocol Violation | 1 | 4 | 0 |
Baseline characteristics
| Characteristic | Placebo | TV-45070 4% | TV-45070 8% | Total |
|---|---|---|---|---|
| Age, Continuous | 58.6 years STANDARD_DEVIATION 15.8 | 57.2 years STANDARD_DEVIATION 15.99 | 57.6 years STANDARD_DEVIATION 16.61 | 57.8 years STANDARD_DEVIATION 16.09 |
| Body Mass Index | 28.15 kg/m^2 STANDARD_DEVIATION 3.798 | 27.42 kg/m^2 STANDARD_DEVIATION 3.457 | 27.30 kg/m^2 STANDARD_DEVIATION 3.452 | 27.62 kg/m^2 STANDARD_DEVIATION 3.58 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 70 Participants | 56 Participants | 53 Participants | 179 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 30 Participants | 43 Participants | 47 Participants | 120 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Height | 165.82 cm STANDARD_DEVIATION 10.355 | 167.27 cm STANDARD_DEVIATION 10.258 | 168.03 cm STANDARD_DEVIATION 8.203 | 167.04 cm STANDARD_DEVIATION 9.668 |
| R1150W Polymorphism Status Heterozygous (positive, AG) | 22 Participants | 17 Participants | 25 Participants | 64 Participants |
| R1150W Polymorphism Status Homozygous common allele (negative, GG) | 78 Participants | 82 Participants | 73 Participants | 233 Participants |
| R1150W Polymorphism Status Homozygous minor allele (positive, AA) | 0 Participants | 1 Participants | 2 Participants | 3 Participants |
| Race/Ethnicity, Customized American Indian or Alaskan Native | 1 Participants | 1 Participants | 1 Participants | 3 Participants |
| Race/Ethnicity, Customized Asian | 1 Participants | 3 Participants | 3 Participants | 7 Participants |
| Race/Ethnicity, Customized Black or African American | 7 Participants | 13 Participants | 17 Participants | 37 Participants |
| Race/Ethnicity, Customized Other | 1 Participants | 2 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized White | 90 Participants | 81 Participants | 79 Participants | 250 Participants |
| Sex: Female, Male Female | 65 Participants | 57 Participants | 50 Participants | 172 Participants |
| Sex: Female, Male Male | 35 Participants | 43 Participants | 50 Participants | 128 Participants |
| Weight | 77.86 kg STANDARD_DEVIATION 15.111 | 77.02 kg STANDARD_DEVIATION 13.775 | 77.41 kg STANDARD_DEVIATION 13.383 | 77.43 kg STANDARD_DEVIATION 14.066 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 100 | 0 / 98 | 0 / 100 |
| other Total, other adverse events | 2 / 100 | 5 / 98 | 1 / 100 |
| serious Total, serious adverse events | 0 / 100 | 1 / 98 | 0 / 100 |
Outcome results
Primary
Change From Baseline to Week 4 in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores Using a Mixed Model for Repeated Measures
The primary efficacy endpoint was the change from baseline to week 4 in the weekly average of the daily average NRS scores. The NRS is a widely-used, standard one-dimensional 11-point scale from 0=no pain to 10=worst pain imaginable as reported by patients. The daily average NRS scores is the average of the 2 NRS scores (recorded in the morning and evening) of average pain, defined as the patient-reported average pain intensity over the prior 12 hours. At least 1 of the 2 daily scores had to be recorded (non-missing) or the daily average was considered missing. Negative change from baseline values indicate a lessening of pain. The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the daily average NRS scores at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of the daily average NRS scores as covariate; and patient as a random effect.
Time frame: Baseline (day -7 to day -1), Week 4 (day 22 to day 28)
Population: Full analysis set; patients from one site are excluded due to lack of data integrity.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| TV-45070 4% | Change From Baseline to Week 4 in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores Using a Mixed Model for Repeated Measures | Baseline | 5.37 units on a scale | Standard Deviation 0.992 |
| TV-45070 4% | Change From Baseline to Week 4 in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores Using a Mixed Model for Repeated Measures | Change from baseline at week 4 | -1.64 units on a scale | Standard Deviation 1.36 |
| TV-45070 8% | Change From Baseline to Week 4 in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores Using a Mixed Model for Repeated Measures | Baseline | 5.60 units on a scale | Standard Deviation 1.236 |
| TV-45070 8% | Change From Baseline to Week 4 in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores Using a Mixed Model for Repeated Measures | Change from baseline at week 4 | -1.71 units on a scale | Standard Deviation 1.5 |
| Placebo | Change From Baseline to Week 4 in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores Using a Mixed Model for Repeated Measures | Baseline | 5.51 units on a scale | Standard Deviation 0.963 |
| Placebo | Change From Baseline to Week 4 in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores Using a Mixed Model for Repeated Measures | Change from baseline at week 4 | -1.90 units on a scale | Standard Deviation 1.67 |
Comparison: The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the daily average NRS scores at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of the daily average NRS scores as covariate; and patient as a random effect.p-value: 0.1395% CI: [-0.094, 0.726]mixed model for repeated measures
Comparison: The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the daily average NRS scores at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of the daily average NRS scores as covariate; and patient as a random effect.p-value: 0.24595% CI: [-0.167, 0.652]mixed model for repeated measures
Secondary
Change From Baseline to Week 4 in the Neuropathic Pain Impact on Quality of Life (NePIQoL) Total Score
NePIQoL is a questionnaire that contains 41 items to evaluate quality of life in patients with neuropathic pain. Each question has responses ranging from strongly agree or always to strongly disagree or never. Questions are scored on a 5-point scale from 1 through 5, where higher scores represent greater pain-related interference in quality of life. Total range is 41 (great quality of life) to 205 (worst quality of life). Negative change from baseline scores indicated an improving quality of life.
Time frame: Baseline (day 1), Week 4 (day 29)
Population: Full analysis set. Participants from one site are excluded due to lack of data integrity.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| TV-45070 4% | Change From Baseline to Week 4 in the Neuropathic Pain Impact on Quality of Life (NePIQoL) Total Score | Baseline | 127.1 units on a scale | Standard Deviation 18.73 |
| TV-45070 4% | Change From Baseline to Week 4 in the Neuropathic Pain Impact on Quality of Life (NePIQoL) Total Score | Change from baseline at week 4 | -11.5 units on a scale | Standard Deviation 17.98 |
| TV-45070 8% | Change From Baseline to Week 4 in the Neuropathic Pain Impact on Quality of Life (NePIQoL) Total Score | Baseline | 126.5 units on a scale | Standard Deviation 20.36 |
| TV-45070 8% | Change From Baseline to Week 4 in the Neuropathic Pain Impact on Quality of Life (NePIQoL) Total Score | Change from baseline at week 4 | 11.3 units on a scale | Standard Deviation 20.09 |
| Placebo | Change From Baseline to Week 4 in the Neuropathic Pain Impact on Quality of Life (NePIQoL) Total Score | Baseline | 127.6 units on a scale | Standard Deviation 19.03 |
| Placebo | Change From Baseline to Week 4 in the Neuropathic Pain Impact on Quality of Life (NePIQoL) Total Score | Change from baseline at week 4 | -12.6 units on a scale | Standard Deviation 19.93 |
p-value: 0.60995% CI: [-3.81, 6.48]ANCOVA
p-value: 0.42795% CI: [-3.05, 7.19]ANCOVA
Secondary
Change From Baseline to Week 4 in the Weekly Average of the Average Numeric Rating Scale (NRS) Pain Scores Recorded in the Evening Using a Mixed Model for Repeated Measures
The NRS is a widely-used, standard one-dimensional 11-point scale from 0=no pain to 10=worst pain imaginable as reported by patients. The NRS pain scores recorded in the evening is defined as the patient-reported average pain intensity over the prior 12 hours. Negative change from baseline values indicate a lessening of pain. The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the evening NRS scores at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of the evening NRS scores as covariate; and patient as a random effect.
Time frame: Baseline (day -7 to day -1), Week 4 (day 22 to day 28)
Population: Full analysis set. Participants from one site are excluded due to lack of data integrity.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| TV-45070 4% | Change From Baseline to Week 4 in the Weekly Average of the Average Numeric Rating Scale (NRS) Pain Scores Recorded in the Evening Using a Mixed Model for Repeated Measures | Baseline | 5.45 units on a scale | Standard Deviation 1.073 |
| TV-45070 4% | Change From Baseline to Week 4 in the Weekly Average of the Average Numeric Rating Scale (NRS) Pain Scores Recorded in the Evening Using a Mixed Model for Repeated Measures | Change from baseline at week 4 | -1.70 units on a scale | Standard Deviation 1.412 |
| TV-45070 8% | Change From Baseline to Week 4 in the Weekly Average of the Average Numeric Rating Scale (NRS) Pain Scores Recorded in the Evening Using a Mixed Model for Repeated Measures | Baseline | 5.66 units on a scale | Standard Deviation 1.32 |
| TV-45070 8% | Change From Baseline to Week 4 in the Weekly Average of the Average Numeric Rating Scale (NRS) Pain Scores Recorded in the Evening Using a Mixed Model for Repeated Measures | Change from baseline at week 4 | -1.73 units on a scale | Standard Deviation 1.506 |
| Placebo | Change From Baseline to Week 4 in the Weekly Average of the Average Numeric Rating Scale (NRS) Pain Scores Recorded in the Evening Using a Mixed Model for Repeated Measures | Baseline | 5.58 units on a scale | Standard Deviation 0.994 |
| Placebo | Change From Baseline to Week 4 in the Weekly Average of the Average Numeric Rating Scale (NRS) Pain Scores Recorded in the Evening Using a Mixed Model for Repeated Measures | Change from baseline at week 4 | -1.96 units on a scale | Standard Deviation 1.745 |
Comparison: The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the average NRS pain scores recorded in the evening at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of the average NRS pain scores recorded in the evening as covariate; and patient as a random effect.p-value: 0.12895% CI: [-0.093, 0.735]mixed model for repeated measures
Comparison: The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the average NRS pain scores recorded in the evening at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of the average NRS pain scores recorded in the evening as covariate; and patient as a random effect.p-value: 0.19495% CI: [-0.14, 0.688]mixed model for repeated measures
Secondary
Change From Baseline to Week 4 in the Weekly Average of the Average Numeric Rating Scale (NRS) Pain Scores Recorded in the Morning Using a Mixed Model for Repeated Measures
The NRS is a widely-used, standard one-dimensional 11-point scale from 0=no pain to 10=worst pain imaginable as reported by patients. The NRS pain scores recorded in the morning is defined as the patient-reported average pain intensity over the prior 12 hours. Negative change from baseline values indicate a lessening of pain. The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the evening NRS scores at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of morning NRS scores as covariate; and patient as a random effect.
Time frame: Baseline (day -7 to day -1), Week 4 (day 22 to day 28)
Population: Full analysis set. Participants from one site are excluded due to lack of data integrity.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| TV-45070 4% | Change From Baseline to Week 4 in the Weekly Average of the Average Numeric Rating Scale (NRS) Pain Scores Recorded in the Morning Using a Mixed Model for Repeated Measures | Baseline | 5.30 units on a scale | Standard Deviation 0.98 |
| TV-45070 4% | Change From Baseline to Week 4 in the Weekly Average of the Average Numeric Rating Scale (NRS) Pain Scores Recorded in the Morning Using a Mixed Model for Repeated Measures | Change from baseline at week 4 | -1.60 units on a scale | Standard Deviation 1.386 |
| TV-45070 8% | Change From Baseline to Week 4 in the Weekly Average of the Average Numeric Rating Scale (NRS) Pain Scores Recorded in the Morning Using a Mixed Model for Repeated Measures | Baseline | 5.53 units on a scale | Standard Deviation 1.226 |
| TV-45070 8% | Change From Baseline to Week 4 in the Weekly Average of the Average Numeric Rating Scale (NRS) Pain Scores Recorded in the Morning Using a Mixed Model for Repeated Measures | Change from baseline at week 4 | -1.68 units on a scale | Standard Deviation 1.548 |
| Placebo | Change From Baseline to Week 4 in the Weekly Average of the Average Numeric Rating Scale (NRS) Pain Scores Recorded in the Morning Using a Mixed Model for Repeated Measures | Baseline | 5.44 units on a scale | Standard Deviation 0.968 |
| Placebo | Change From Baseline to Week 4 in the Weekly Average of the Average Numeric Rating Scale (NRS) Pain Scores Recorded in the Morning Using a Mixed Model for Repeated Measures | Change from baseline at week 4 | -1.84 units on a scale | Standard Deviation 1.623 |
Comparison: The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the average NRS pain scores recorded in the morning at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of the average NRS pain scores recorded in the morning as covariate; and patient as a random effect.p-value: 0.17795% CI: [-0.128, 0.691]mixed model for repeated measures
Comparison: The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the average NRS pain scores recorded in the morning at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of the average NRS pain scores recorded in the morning as covariate; and patient as a random effect.p-value: 0.32595% CI: [-0.204, 0.614]mixed model for repeated measures
Secondary
Change From Baseline to Week 4 in the Weekly Average of the Worst Numeric Rating Scale (NRS) Pain Scores Recorded in the Evening Using a Mixed Model for Repeated Measures
The NRS is a widely-used, standard one-dimensional 11-point scale from 0=no pain to 10=worst pain imaginable as reported by patients. The worst pain is defined as the patient-reported worst pain intensity over the prior 24 hours. Negative change from baseline values indicate a lessening of pain. The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the worst pain NRS scores at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of the evening NRS scores as covariate; and patient as a random effect.
Time frame: Baseline (day -7 to day -1), Week 4 (day 22 to day 28)
Population: Full analysis set. Participants from one site are excluded due to lack of data integrity.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| TV-45070 4% | Change From Baseline to Week 4 in the Weekly Average of the Worst Numeric Rating Scale (NRS) Pain Scores Recorded in the Evening Using a Mixed Model for Repeated Measures | Baseline | 6.09 units on a scale | Standard Deviation 1.06 |
| TV-45070 4% | Change From Baseline to Week 4 in the Weekly Average of the Worst Numeric Rating Scale (NRS) Pain Scores Recorded in the Evening Using a Mixed Model for Repeated Measures | Change from baseline at week 4 | -1.73 units on a scale | Standard Deviation 1.576 |
| TV-45070 8% | Change From Baseline to Week 4 in the Weekly Average of the Worst Numeric Rating Scale (NRS) Pain Scores Recorded in the Evening Using a Mixed Model for Repeated Measures | Baseline | 6.35 units on a scale | Standard Deviation 1.378 |
| TV-45070 8% | Change From Baseline to Week 4 in the Weekly Average of the Worst Numeric Rating Scale (NRS) Pain Scores Recorded in the Evening Using a Mixed Model for Repeated Measures | Change from baseline at week 4 | -1.83 units on a scale | Standard Deviation 1.657 |
| Placebo | Change From Baseline to Week 4 in the Weekly Average of the Worst Numeric Rating Scale (NRS) Pain Scores Recorded in the Evening Using a Mixed Model for Repeated Measures | Baseline | 6.09 units on a scale | Standard Deviation 1.041 |
| Placebo | Change From Baseline to Week 4 in the Weekly Average of the Worst Numeric Rating Scale (NRS) Pain Scores Recorded in the Evening Using a Mixed Model for Repeated Measures | Change from baseline at week 4 | -1.97 units on a scale | Standard Deviation 1.883 |
Comparison: The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the worst NRS pain scores recorded in the evening at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of the worst NRS pain scores recorded in the evening as covariate; and patient as a random effect.p-value: 0.20295% CI: [-0.158, 0.741]mixed model for repeated measures
Comparison: The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the worst NRS pain scores recorded in the evening at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of the worst NRS pain scores recorded in the evening as covariate; and patient as a random effect.p-value: 0.45795% CI: [-0.28, 0.621]mixed model for repeated measures
Secondary
Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Brush-Evoked Allodynia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM)
Allodynia refers to central pain sensitization (increased response of neurons) following normally non-painful, often repetitive, stimulation. In this case, pain evoked by innocuous brush is measured on an 11-point NRS where 0=no pain and 11=worst pain imaginable as reported by patients Negative change from baseline scores indicate improvement (lessening) of pain.
Time frame: Baseline (day 1 prior to dosing), Weeks 2 (day 15) and Week 4 (day 29)
Population: Full analysis set. Participants from one site are excluded due to lack of data integrity. Participants from two other sites are excluded dince the two sites incorrectly assessed allodynia. If brush-evoked allodynia was not present at screening, it was not rechecked on subsequent visits.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| TV-45070 4% | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Brush-Evoked Allodynia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 2 | -0.7 units on a scale | Standard Deviation 1.47 |
| TV-45070 4% | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Brush-Evoked Allodynia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Baseline | 1.6 units on a scale | Standard Deviation 1.54 |
| TV-45070 4% | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Brush-Evoked Allodynia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 4 | -0.7 units on a scale | Standard Deviation 1.45 |
| TV-45070 8% | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Brush-Evoked Allodynia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 2 | -1.0 units on a scale | Standard Deviation 2.25 |
| TV-45070 8% | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Brush-Evoked Allodynia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Baseline | 1.8 units on a scale | Standard Deviation 2.28 |
| TV-45070 8% | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Brush-Evoked Allodynia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 4 | -0.7 units on a scale | Standard Deviation 2.3 |
| Placebo | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Brush-Evoked Allodynia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Baseline | 2.0 units on a scale | Standard Deviation 2.24 |
| Placebo | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Brush-Evoked Allodynia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 4 | -0.7 units on a scale | Standard Deviation 1.76 |
| Placebo | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Brush-Evoked Allodynia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 2 | -0.8 units on a scale | Standard Deviation 1.53 |
Comparison: Change from baseline at week 2 The inferential model includes study center, week, treatment, and treatment by week interaction as the fixed factors; baseline as a covariate and unstructured variance-covariance structure in the initial model.p-value: 0.55695% CI: [-0.61, 0.33]mixed model for repeated measures
Comparison: Change from baseline at week 2 The inferential model includes study center, week, treatment, and treatment by week interaction as the fixed factors; baseline as a covariate and unstructured variance-covariance structure in the initial model.p-value: 0.48295% CI: [-0.65, 0.31]mixed model for repeated measures
Comparison: Change from baseline at week 4. The inferential model includes study center, week, treatment, and treatment by week interaction as the fixed factors; baseline as a covariate and unstructured variance-covariance structure in the initial model.p-value: 0.33395% CI: [-0.81, 0.28]mixed model for repeated measures
Comparison: Change from baseline at week 4 The inferential model includes study center, week, treatment, and treatment by week interaction as the fixed factors; baseline as a covariate and unstructured variance-covariance structure in the initial model.p-value: 0.83395% CI: [-0.62, 0.5]mixed model for repeated measures
Secondary
Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Punctate-Evoked Hyperalgesia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM)
Hyperalgesia refers to increased pain from a stimulus that normally provokes pain. In this case, pain is evoked by punctate skin stimulation using a Medipin® and is measured on an 11-point NRS where 0=no pain and 11=worst pain imaginable as reported by patients. Negative change from baseline scores indicate improvement (lessening) of pain. The MMRM used pooled study center, week, treatment, and treatment by week interaction as fixed factors and patient as a random factor. The unstructured covariance matrix for repeated observations within patients was used.
Time frame: Baseline (day 1 prior to dosing), Weeks 2 (day 15) and Week 4 (day 29)
Population: Full analysis set. Participants from one site are excluded due to lack of data integrity. Participants from two other sites are excluded since the two sites incorrectly assessed allodynia. If punctate-evoked hyperalgesia was not present at screening, it was not rechecked on subsequent visits.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| TV-45070 4% | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Punctate-Evoked Hyperalgesia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 2 | -1.0 units on a scale | Standard Deviation 2.02 |
| TV-45070 4% | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Punctate-Evoked Hyperalgesia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Baseline | 2.4 units on a scale | Standard Deviation 2.03 |
| TV-45070 4% | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Punctate-Evoked Hyperalgesia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 4 | -1.0 units on a scale | Standard Deviation 2.08 |
| TV-45070 8% | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Punctate-Evoked Hyperalgesia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 2 | -1.3 units on a scale | Standard Deviation 2.16 |
| TV-45070 8% | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Punctate-Evoked Hyperalgesia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Baseline | 3.0 units on a scale | Standard Deviation 2.48 |
| TV-45070 8% | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Punctate-Evoked Hyperalgesia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 4 | -1.5 units on a scale | Standard Deviation 2.36 |
| Placebo | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Punctate-Evoked Hyperalgesia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Baseline | 2.8 units on a scale | Standard Deviation 2.57 |
| Placebo | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Punctate-Evoked Hyperalgesia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 4 | -1.4 units on a scale | Standard Deviation 2 |
| Placebo | Change From Baseline to Weeks 2 and 4 in Maximal Intensity of Punctate-Evoked Hyperalgesia as Measured on an 11-point Numeric Rating Scale (NRS) Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 2 | -1.1 units on a scale | Standard Deviation 1.91 |
Comparison: Change from baseline at week 2 The inferential model includes study center, week, treatment, and treatment by week interaction as the fixed factors; baseline as a covariate and unstructured variance-covariance structure in the initial model.p-value: 0.56395% CI: [-0.75, 0.41]mixed model for repeated measures
Comparison: Change from baseline at week 2. The inferential model includes study center, week, treatment, and treatment by week interaction as the fixed factors; baseline as a covariate and unstructured variance-covariance structure in the initial model.p-value: 0.80495% CI: [-0.64, 0.5]mixed model for repeated measures
Comparison: Change from baseline at week 4 The inferential model includes study center, week, treatment, and treatment by week interaction as the fixed factors; baseline as a covariate and unstructured variance-covariance structure in the initial model.p-value: 0.71495% CI: [-0.49, 0.71]mixed model for repeated measures
Comparison: Change from baseline at week 4. The inferential model includes study center, week, treatment, and treatment by week interaction as the fixed factors; baseline as a covariate and unstructured variance-covariance structure in the initial model.p-value: 0.87195% CI: [-0.64, 0.55]mixed model for repeated measures
Secondary
Change From Baseline to Weeks 2 and 4 in the Daily Sleep Interference Scale (DSIS) Using a Mixed Model for Repeated Measures
DSIS is an 11-point scale that asks the patient to select the number that best describes how much your pain has interfered with your sleep during the past 24 hours. Response options range from 0 (Did not interfere with sleep) to 10 (Completely interfered with sleep/unable to sleep due to pain). Negative change from baseline scores indicate improvement (lessening) of how much pain interfered with sleep. The MMRM used pooled study center, week, treatment, and treatment by week interaction as fixed factors and patient as a random factor.
Time frame: Baseline (day 1 prior to dosing), Weeks 2 (day 15) and Week 4 (day 29)
Population: Full analysis set. Participants from one site are excluded due to lack of data integrity. Data collected beyond last dose of study medication plus 3 days are excluded from the analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| TV-45070 4% | Change From Baseline to Weeks 2 and 4 in the Daily Sleep Interference Scale (DSIS) Using a Mixed Model for Repeated Measures | Change from baseline at week 2 | -1.1 units on a scale | Standard Deviation 1.54 |
| TV-45070 4% | Change From Baseline to Weeks 2 and 4 in the Daily Sleep Interference Scale (DSIS) Using a Mixed Model for Repeated Measures | Baseline | 4.5 units on a scale | Standard Deviation 1.94 |
| TV-45070 4% | Change From Baseline to Weeks 2 and 4 in the Daily Sleep Interference Scale (DSIS) Using a Mixed Model for Repeated Measures | Change from baseline at week 4 | -1.4 units on a scale | Standard Deviation 1.78 |
| TV-45070 8% | Change From Baseline to Weeks 2 and 4 in the Daily Sleep Interference Scale (DSIS) Using a Mixed Model for Repeated Measures | Change from baseline at week 2 | -1.1 units on a scale | Standard Deviation 1.99 |
| TV-45070 8% | Change From Baseline to Weeks 2 and 4 in the Daily Sleep Interference Scale (DSIS) Using a Mixed Model for Repeated Measures | Baseline | 4.4 units on a scale | Standard Deviation 2.26 |
| TV-45070 8% | Change From Baseline to Weeks 2 and 4 in the Daily Sleep Interference Scale (DSIS) Using a Mixed Model for Repeated Measures | Change from baseline at week 4 | -1.5 units on a scale | Standard Deviation 2.16 |
| Placebo | Change From Baseline to Weeks 2 and 4 in the Daily Sleep Interference Scale (DSIS) Using a Mixed Model for Repeated Measures | Baseline | 4.4 units on a scale | Standard Deviation 2 |
| Placebo | Change From Baseline to Weeks 2 and 4 in the Daily Sleep Interference Scale (DSIS) Using a Mixed Model for Repeated Measures | Change from baseline at week 4 | -1.7 units on a scale | Standard Deviation 2.24 |
| Placebo | Change From Baseline to Weeks 2 and 4 in the Daily Sleep Interference Scale (DSIS) Using a Mixed Model for Repeated Measures | Change from baseline at week 2 | -1.3 units on a scale | Standard Deviation 1.99 |
Comparison: Change from baseline at Week 2 The inferential model includes study center, week, treatment, and treatment by week interaction as the fixed factors; baseline as a covariate and unstructured variance-covariance structure in the initial model.p-value: 0.31195% CI: [-0.22, 0.7]mixed model for repeated measures
Comparison: Change from baseline at week 2 The inferential model includes study center, week, treatment, and treatment by week interaction as the fixed factors; baseline as a covariate and unstructured variance-covariance structure in the initial model.p-value: 0.26295% CI: [-0.2, 0.73]mixed model for repeated measures
Comparison: Change from baseline at week 4 The inferential model includes study center, week, treatment, and treatment by week interaction as the fixed factors; baseline as a covariate and unstructured variance-covariance structure in the initial model.p-value: 0.06595% CI: [-0.03, 0.97]mixed model for repeated measures
Comparison: Change from baseline at week 4 The inferential model includes study center, week, treatment, and treatment by week interaction as the fixed factors; baseline as a covariate and unstructured variance-covariance structure in the initial model.p-value: 0.29695% CI: [-0.23, 0.76]mixed model for repeated measures
Secondary
Change From Baseline to Weeks 2 and 4 in the Neuropathic Pain Symptom Inventory (NPSI) Total Score Using a Mixed Model for Repeated Measures (MMRM)
NPSI is a patient-reported questionnaire to evaluate the severity of different symptoms of neuropathic pain. The questionnaire contains 10 descriptors representing 5 distinct dimensions of pain: burning pain, deep pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia, plus 2 temporal items. Descriptors are scored from 0 through 10, where higher scores represent worse pain. The total score is the sum of the scores of the 10 descriptors (Bouhassira et al 2004). The total score ranges from 0 (no pain) through 100 (worst pain imaginable). If the score for one question was missing the total score was computed as 10 times sum of scores of 9 descriptors divided by 9. If more than one question was missing then the total score was missing. Negative change from baseline scores indicated less pain. The MMRM used pooled study center, week, treatment, and treatment by week interaction as fixed factors and patient as a random factor.
Time frame: Baseline (day 1 prior to dosing), Weeks 2 (day 15) and Week 4 (day 29)
Population: Full analysis set. Participants from one site are excluded due to lack of data integrity.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| TV-45070 4% | Change From Baseline to Weeks 2 and 4 in the Neuropathic Pain Symptom Inventory (NPSI) Total Score Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 2 | -8.1 units on a scale | Standard Deviation 14.13 |
| TV-45070 4% | Change From Baseline to Weeks 2 and 4 in the Neuropathic Pain Symptom Inventory (NPSI) Total Score Using a Mixed Model for Repeated Measures (MMRM) | Baseline | 41.9 units on a scale | Standard Deviation 16.45 |
| TV-45070 4% | Change From Baseline to Weeks 2 and 4 in the Neuropathic Pain Symptom Inventory (NPSI) Total Score Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 4 | -13.1 units on a scale | Standard Deviation 15.76 |
| TV-45070 8% | Change From Baseline to Weeks 2 and 4 in the Neuropathic Pain Symptom Inventory (NPSI) Total Score Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 2 | -9.9 units on a scale | Standard Deviation 15.65 |
| TV-45070 8% | Change From Baseline to Weeks 2 and 4 in the Neuropathic Pain Symptom Inventory (NPSI) Total Score Using a Mixed Model for Repeated Measures (MMRM) | Baseline | 44.0 units on a scale | Standard Deviation 16.5 |
| TV-45070 8% | Change From Baseline to Weeks 2 and 4 in the Neuropathic Pain Symptom Inventory (NPSI) Total Score Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 4 | -14.3 units on a scale | Standard Deviation 15.47 |
| Placebo | Change From Baseline to Weeks 2 and 4 in the Neuropathic Pain Symptom Inventory (NPSI) Total Score Using a Mixed Model for Repeated Measures (MMRM) | Baseline | 44.0 units on a scale | Standard Deviation 15.18 |
| Placebo | Change From Baseline to Weeks 2 and 4 in the Neuropathic Pain Symptom Inventory (NPSI) Total Score Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 4 | -16.8 units on a scale | Standard Deviation 17.78 |
| Placebo | Change From Baseline to Weeks 2 and 4 in the Neuropathic Pain Symptom Inventory (NPSI) Total Score Using a Mixed Model for Repeated Measures (MMRM) | Change from baseline at week 2 | -10.8 units on a scale | Standard Deviation 14.68 |
Comparison: Change from baseline at Week 2 The MMRM used pooled study center, week, treatment, and treatment by week interaction as fixed factors and patient as a random factor. The unstructured covariance matrix for repeated observations within patients was used.p-value: 0.25195% CI: [-1.55, 5.92]mixed model for repeated measures
Comparison: Change from baseline at Week 2. The MMRM used pooled study center, week, treatment, and treatment by week interaction as fixed factors and patient as a random factor. The unstructured covariance matrix for repeated observations within patients was used.p-value: 0.49595% CI: [-2.46, 5.07]mixed model for repeated measures
Comparison: Change from baseline at Week 4. The MMRM used pooled study center, week, treatment, and treatment by week interaction as fixed factors and patient as a random factor. The unstructured covariance matrix for repeated observations within patients was used.p-value: 0.12395% CI: [-0.84, 7.06]mixed model for repeated measures
Comparison: Change from baseline at Week 4. The MMRM used pooled study center, week, treatment, and treatment by week interaction as fixed factors and patient as a random factor. The unstructured covariance matrix for repeated observations within patients was used.p-value: 0.1695% CI: [-1.12, 6.77]miex model for repeated measures
Secondary
Kaplan-Meier Estimates for First Time to Reach 30% or More Sustained Improvement in Weekly Average of the Daily Average NRS Pain Scores
Percent improvement is calculated as 100\*(the weekly average of the daily average NRS pain score - weekly average of the daily average NRS pain scores at baseline \[days -7 to -1\])/weekly average of the daily average NRS pain scores at baseline. Patients who do not reach \>= 30% improvement are censored at their last non-missing weekly average. Patients who reach \>= 30% improvement, but the improvement is not sustained through the end of the treatment period are censored at their last non-missing weekly average. For patients who reach \>= 30% improvement that is sustained through the end through the end of the of the treatment, the time \>= 30% improvement is first reached is used.
Time frame: Baseline (days -7 to -1), Week 1 (days 1-7), Week 2 (day 8-14), Week 3 (days 15-21), Week 4 (days 22-29)
Population: Full analysis set. Participants from one site are excluded due to lack of data integrity.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| TV-45070 4% | Kaplan-Meier Estimates for First Time to Reach 30% or More Sustained Improvement in Weekly Average of the Daily Average NRS Pain Scores | NA days |
| TV-45070 8% | Kaplan-Meier Estimates for First Time to Reach 30% or More Sustained Improvement in Weekly Average of the Daily Average NRS Pain Scores | NA days |
| Placebo | Kaplan-Meier Estimates for First Time to Reach 30% or More Sustained Improvement in Weekly Average of the Daily Average NRS Pain Scores | NA days |
p-value: 0.245Regression, Cox
p-value: 0.304Regression, Cox
Secondary
Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM)
PGIC is a standardized self-report tool that measures the change in a patient's overall status rating since the start of treatment on 7-point scale (Hurst and Bolton 2004). The 7-point scale is defined as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. The MMRM used pooled study center, week, treatment, and treatment by week interaction as fixed factors and patient as a random factor.
Time frame: Weeks 2 (day 15) and Week 4 (day 29)
Population: Full analysis set. Participants from one site are excluded due to lack of data integrity. Data collected beyond last dose of study medication plus 3 days are excluded from the analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| TV-45070 4% | Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 2 | 2.9 units on a scale | Standard Deviation 0.87 |
| TV-45070 4% | Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 4 | 2.6 units on a scale | Standard Deviation 1.08 |
| TV-45070 8% | Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 2 | 2.9 units on a scale | Standard Deviation 0.92 |
| TV-45070 8% | Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 4 | 2.5 units on a scale | Standard Deviation 1.12 |
| Placebo | Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 2 | 2.7 units on a scale | Standard Deviation 0.82 |
| Placebo | Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 4 | 2.4 units on a scale | Standard Deviation 1.07 |
Comparison: Week 2 Mixed model for repeated measures (MMRM) with pooled study center, week, treatment, and treatment by week interaction as fixed factors and patient as a random factor. The unstructured covariance matrix for repeated observations within patients was used.p-value: 0.16695% CI: [-0.07, 0.43]mixed model for repeated measures
Comparison: Week 2 Mixed model for repeated measures (MMRM) with pooled study center, week, treatment, and treatment by week interaction as fixed factors and patient as a random factor. The unstructured covariance matrix for repeated observations within patients was used.p-value: 0.04695% CI: [0, 0.51]mixed model for repeated measures
Comparison: Week 4 Mixed model for repeated measures (MMRM) with pooled study center, week, treatment, and treatment by week interaction as fixed factors and patient as a random factor. The unstructured covariance matrix for repeated observations within patients was used.p-value: 0.15295% CI: [-0.08, 0.53]mixed model for repeated measures
Comparison: Week 4 Mixed model for repeated measures (MMRM) with pooled study center, week, treatment, and treatment by week interaction as fixed factors and patient as a random factor. The unstructured covariance matrix for repeated observations within patients was used.p-value: 0.34295% CI: [-0.16, 0.46]mixed model for repeated measures
Secondary
Participants With Treatment-Emergent Adverse Events
An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
Time frame: day 1 up to day 57
Population: Safety population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TV-45070 4% | Participants With Treatment-Emergent Adverse Events | Any treatment-emergent adverse event | 15 Participants |
| TV-45070 4% | Participants With Treatment-Emergent Adverse Events | Severe TEAE | 0 Participants |
| TV-45070 4% | Participants With Treatment-Emergent Adverse Events | Treatment-related TEAE | 5 Participants |
| TV-45070 4% | Participants With Treatment-Emergent Adverse Events | Deaths | 0 Participants |
| TV-45070 4% | Participants With Treatment-Emergent Adverse Events | Serious TEAE | 0 Participants |
| TV-45070 4% | Participants With Treatment-Emergent Adverse Events | Withdrawn from treatment due to TEAE | 4 Participants |
| TV-45070 8% | Participants With Treatment-Emergent Adverse Events | Withdrawn from treatment due to TEAE | 4 Participants |
| TV-45070 8% | Participants With Treatment-Emergent Adverse Events | Any treatment-emergent adverse event | 32 Participants |
| TV-45070 8% | Participants With Treatment-Emergent Adverse Events | Deaths | 0 Participants |
| TV-45070 8% | Participants With Treatment-Emergent Adverse Events | Serious TEAE | 1 Participants |
| TV-45070 8% | Participants With Treatment-Emergent Adverse Events | Severe TEAE | 1 Participants |
| TV-45070 8% | Participants With Treatment-Emergent Adverse Events | Treatment-related TEAE | 10 Participants |
| Placebo | Participants With Treatment-Emergent Adverse Events | Severe TEAE | 0 Participants |
| Placebo | Participants With Treatment-Emergent Adverse Events | Treatment-related TEAE | 11 Participants |
| Placebo | Participants With Treatment-Emergent Adverse Events | Withdrawn from treatment due to TEAE | 3 Participants |
| Placebo | Participants With Treatment-Emergent Adverse Events | Deaths | 0 Participants |
| Placebo | Participants With Treatment-Emergent Adverse Events | Any treatment-emergent adverse event | 24 Participants |
| Placebo | Participants With Treatment-Emergent Adverse Events | Serious TEAE | 0 Participants |
Secondary
Percentage of Participants With >=30% and >=50% Improvement From Baseline in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores at Week 4 Using a Mixed Model for Repeated Measures
The NRS is a 11-point scale from 0=no pain to 10=worst pain imaginable as reported by patients. The daily average NRS scores is the average of the 2 NRS scores (recorded in the morning and evening) of average pain, defined as the patient-reported average pain intensity over the prior 12 hours. Percent improvement is calculated as 100 × (the weekly average of the daily average NRS pain score at week 4 - weekly average of the daily average NRS pain scores at baseline /weekly average of the daily average NRS pain scores at baseline. Patients missing a week 4 average are considered non-responders (\<50% improvement or \<30% improvement). The Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the daily average NRS scores at week 4 as the dependent variable; week, pooled study center, treatment, and treatment by visit interaction as fixed factors, baseline weekly average of the daily average NRS scores as covariate; and patient as a random effect.
Time frame: Baseline (day -7 to day -1), Week 4 (day 22 to day 28)
Population: Full analysis set. Participants from one site are excluded due to lack of data integrity.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TV-45070 4% | Percentage of Participants With >=30% and >=50% Improvement From Baseline in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores at Week 4 Using a Mixed Model for Repeated Measures | >=50% improvement from baseline | 22.4 percentage of participants |
| TV-45070 4% | Percentage of Participants With >=30% and >=50% Improvement From Baseline in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores at Week 4 Using a Mixed Model for Repeated Measures | >=30% improvement from baseline | 43.9 percentage of participants |
| TV-45070 8% | Percentage of Participants With >=30% and >=50% Improvement From Baseline in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores at Week 4 Using a Mixed Model for Repeated Measures | >=50% improvement from baseline | 25.5 percentage of participants |
| TV-45070 8% | Percentage of Participants With >=30% and >=50% Improvement From Baseline in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores at Week 4 Using a Mixed Model for Repeated Measures | >=30% improvement from baseline | 43.9 percentage of participants |
| Placebo | Percentage of Participants With >=30% and >=50% Improvement From Baseline in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores at Week 4 Using a Mixed Model for Repeated Measures | >=30% improvement from baseline | 47.0 percentage of participants |
| Placebo | Percentage of Participants With >=30% and >=50% Improvement From Baseline in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores at Week 4 Using a Mixed Model for Repeated Measures | >=50% improvement from baseline | 28.0 percentage of participants |
Comparison: \>=30% improvement. P-value, odds ratio and CI for odds ratio are calculated using logistic model including response (yes/no) as dependent variable, treatment group and pooled study sites as factors.p-value: 0.81595% CI: [0.456, 1.856]Regression, Logistic
Comparison: \>=30% improvement. P-value, odds ratio and CI for odds ratio are calculated using logistic model including response (yes/no) as dependent variable, treatment group and pooled study sites as factors.p-value: 0.89395% CI: [0.52, 2.117]Regression, Logistic
Comparison: \>=50% improvement. P-value, odds ratio and CI for odds ratio are calculated using logistic model including response (yes/no) as dependent variable, treatment group and pooled study sites as factors.p-value: 0.4395% CI: [0.357, 1.55]Regression, Logistic
Comparison: \>=50% improvement. P-value, odds ratio and CI for odds ratio are calculated using logistic model including response (yes/no) as dependent variable, treatment group and pooled study sites as factors.p-value: 0.96795% CI: [0.494, 2.088]Regression, Logistic